Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.55 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697045 | 0.87 | SIGMAR1 (0.64) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A2 | |
| SCHEMBL12289294 | 0.81 | SLC6A4 (0.61) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A4 | |
| SCHEMBL9341390 | 0.81 | SLC6A4 (0.61) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A4 | |
| SCHEMBL172645 | 0.81 | SLC6A4 (0.61) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A4 | |
| SCHEMBL10062064 | 0.79 | SIGMAR1 (0.55) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A2 | |
| SCHEMBL1764932 | 0.79 | TAAR1 (0.55) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A2 | |
| SCHEMBL10797818 | 0.79 | TAAR1 (0.55) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A2 | |
| SCHEMBL693965 | 0.79 | MAPK1 (0.57) | SIGMAR1TAAR1SLC18A2EPHX1OPRM1 | |
| SCHEMBL21550512 | 0.79 | TAAR1 (0.55) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A2 | |
| SCHEMBL18995778 | 0.79 | SIGMAR1 (0.55) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101302-A1 | NOVEL PRECURSOR MOLECULES FOR F-18 LABELLED PET TRACERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101302-A1 | NOVEL PRECURSOR MOLECULES FOR F-18 LABELLED PET TRACERS | MPI, TMEM14C, FDPS | SIGMAR1 2066/4885TAAR1 1473/4885SLC18A2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.